跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2022/07/044491
CTRI/2022/07/044491已完成未知

An open label, multicenter, balanced, randomized, two-treatment, four-period, two-sequence, full replicate crossover, single dose, pharmacokinetic bioequivalence study of Capecitabine Tablets USP, 500 mg of Novugen Oncology Sdn. Bhd. with Xeloda® (Capecitabine) 500 mg Film-Coated Tablets manufactured by Roche Pharma AG, Germany following single oral dose of 2000 mg (4 X 500 mg) in adult human cancer patients under fed conditions.

ovugen Oncology Sdn Bhd0 个研究点目标入组 40 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
未知
状态
已完成
发起方
入组人数
40
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Ba/be

入排标准

入选标准

  • •Subjects will be considered eligible for the study based on the following criteria:
  • •1. Willing and able to provide voluntary informed consent and able to comply with protocol requirements
  • •2. Male or Female aged 18 to 65 years (both inclusive) having body mass index at least 17.00 calculated as weight in kg per height in m2.
  • •3. Patients having Body Surface Area between 1.27 to 1.92 m2 (both inclusive) measured as per the Dubois formula.
  • •4. Patients with histopathologically or cytologically confirmed colon or colorectal or breast cancer.
  • •5. Patients with DukesC colon cancer who have undergone complete resection of the primary tumor and when treatment with fluoropyrimidine therapy alone is preferred. Or Patients with metastatic colorectal carcinoma in whom treatment with fluoropyrimidine therapy alone is preferred. Or Patients with locally advanced or metastatic breast cancer, after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
  • •6. Patients requiring a daily dose of Capecitabine monotherapy and stabilized at least on one cycle of Capecitabine chemotherapy (ex.twice daily at a dose of 1250 mg per m2 for 2 weeks followed by one week rest period).
  • •7. Cardiac ejection fraction Greater than or equal to 50Percentby echocardiogram at screening.
  • •8. Eastern Cooperative Oncology Group (ECOG) performance status Lessthan or equal to2.
  • •9. Acceptable hematology status:
  • •a. Hemoglobin Greater than or equal to 9 g per dL
  • •b. Absolute neutrophil count (ANC) Greater than or equal to 1500 cells per mm3
  • •c. Platelet count Greater than or equal to 100,000 cells per mm3
  • •d. WBC Greater than or equal to 3000 cells per mm3
  • •10. Acceptable liver function:
  • •a. Alanine aminotransferase (ALT) Lessthan or equal to2.5 X ULN
  • •b. Aspartate aminotransferase (AST) Lessthan or equal to2.5 X ULN
  • •c. Bilirubin Lessthan or equal to1.5 X ULN
  • •d. Alkaline phosphatase Lessthan or equal to2.5 X ULN
  • •11. Patients with creatinine clearance Greaterthan 60 mL pe rminute calculated as per Cockcroft and Gault Formula.
  • •12. Patients with life expectancy of at least 3 months at the time of enrolment.
  • •13. Non-smokers
  • •14. Male patients must agree to use an effective method of contraception from screening, during treatment and for at least 3 months after the last dose of capecitabine.
  • •15. Female patients with negative serum pregnancy test at screening and negative urine pregnancy test on Day 0.
  • •16. Women of child bearing potential, (defined as women physiologically capable of becoming pregnant, unless they are using effective method of contraception during dosing of the investigational product) practicing two acceptable methods of contraception during treatment and for 6 months after the last dose of capecitabine.
  • •Acceptable methods of contraception are
  • •a. Oral or parenteral (injection) or patch or implant hormonal contraception which has been used continuously for at least one month prior to the first dose of study medication
  • •b. Intrauterine device (IUD) or intrauterine system
  • •c. Double barrier method of contraception (Condom and occlusive cap or condom and spermicidal agent)
  • •d. Male sterilization (at least 6 months prior to the screening, should be the sole male partner for that patient)
  • •e. Female sterili

排除标准

  • •Subjects will be excluded from the study based on the following criteria:
  • •1.Known hypersensitivity or contraindication to fluoropyrimidine therapy or to any of the components of investigational product.
  • •2.Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption
  • •3.Known central nervous system (CNS) metastasis.
  • •4.Known deficiency of dihydropyrimidine dehydrogenase (DPD)
  • •5.Patients with history of cardiac disease
  • •6.Major surgical procedure (including periodontal) within 28 days of first dose of Investigational Product.
  • •7.Surgical or other non-healing wounds.
  • •8.Patients with major mucocutaneous and dermatological abnormality.
  • •9.Patients with coagulopathy.
  • •10.Patients with positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV).
  • •11.Patients with suspected signs and symptoms of COVID-19/confirmed novel coronavirus infection (COVID-19) or with a recent history (within 14 days) of travel/contact with any COVID-19 positive patient/isolation/quarantine.
  • •12.Patients with positive urine screen for drugs of abuse.
  • •13.Patients with positive urine alcohol test
  • •14.History of other malignancies in the last 5 years (except in situ cancer or basal or squamous cell skin cancer).
  • •15.Has not recovered to Grade 0 or 1 toxicity from previous anticancer treatments or previous investigational agents. Exceptions are alopecia (any grade is acceptable), haemoglobin Greater than or equal to 9.0 g/dL, fatigue (Grade 2 is acceptable), and peripheral neuropathy (stable Grade 2 is acceptable) (As per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], V5.0)
  • •16.Participation in any clinical study within 90 days prior to receiving the first dose of Investigational Product.
  • •17.Loss of blood Greater than or equal 350 mL within 90 days prior to receiving the first dose of investigational product for the current study.
  • •18.Patients taking or scheduled to receive any of the prohibited medications (as per appendix B)
  • •19.Any other medical condition or uncontrolled systemic disease (e.g. cardiovascular disease, hypertension, diabetes mellitus etc.) that, in the opinion of the Investigator, may make it undesirable for the patient to participate in the study including but not limited to cirrhosis or psychiatric illness/social situations that would limit adherence to study requirements.
  • •20. Lactating women.

研究者

发起方
ovugen Oncology Sdn Bhd

相似试验

进行中（未招募）
不适用
A study of Capecitabine 200 mg/ ml with Xeloda 500 mg (Capecitabine) at a dose of 2000 mg in adult human cancer patients under fed conditions.
CTRI/2020/10/028417Shilpa Medicare Limited
进行中（未招募）
Unknown
euprolide acetate in the treatment of Prostate Cancer.
CTRI/2023/09/057619Pharmathen S.A.
已完成
不适用
Imatinib Mesylate Oral Solution 400mg/5ml with Gleevec® (Imatinib mesylate) Tablets 400mg in adult human subjects with Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumors under fed condition.
CTRI/2020/03/024404Shilpa Medicare Limited35
已完成
不适用
Open label multicenter randomized parallel single-period single dose bio equivalence study of Leuprolide acetate 30 mg in adult male subjects with advanced prostaticcancer undergoing initial therapy.
CTRI/2020/10/028442Pharmathen SA32
已完成
不适用
To evaluate bioavailability of oral Capecitabine in adult human cancer patients under fed conditions
CTRI/2021/06/034321ShilpaMedicareLimited35